284 related articles for article (PubMed ID: 38543629)
21. Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.
Marjuki H; Mishin VP; Chesnokov AP; De La Cruz JA; Davis CT; Villanueva JM; Fry AM; Gubareva LV
J Virol; 2015 May; 89(10):5419-26. PubMed ID: 25740997
[TBL] [Abstract][Full Text] [Related]
22. Virtual screening, ADME/T, and binding free energy analysis of anti-viral, anti-protease, and anti-infectious compounds against NSP10/NSP16 methyltransferase and main protease of SARS CoV-2.
Maurya SK; Maurya AK; Mishra N; Siddique HR
J Recept Signal Transduct Res; 2020 Dec; 40(6):605-612. PubMed ID: 32476594
[TBL] [Abstract][Full Text] [Related]
23. Type II transmembrane serine proteases as potential target for anti-influenza drug discovery.
Shin WJ; Seong BL
Expert Opin Drug Discov; 2017 Nov; 12(11):1139-1152. PubMed ID: 28870104
[TBL] [Abstract][Full Text] [Related]
24. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection.
Chen SH; Tan SL
Curr Med Chem; 2005; 12(20):2317-42. PubMed ID: 16181135
[TBL] [Abstract][Full Text] [Related]
25. Structural similarities between SARS-CoV2 3CL
Bafna K; Cioffi CL; Krug RM; Montelione GT
Front Chem; 2022; 10():948553. PubMed ID: 36353143
[TBL] [Abstract][Full Text] [Related]
26. Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs.
Tompa DR; Immanuel A; Srikanth S; Kadhirvel S
Int J Biol Macromol; 2021 Mar; 172():524-541. PubMed ID: 33454328
[TBL] [Abstract][Full Text] [Related]
27. Strategies for development of Dengue virus inhibitors.
Noble CG; Chen YL; Dong H; Gu F; Lim SP; Schul W; Wang QY; Shi PY
Antiviral Res; 2010 Mar; 85(3):450-62. PubMed ID: 20060421
[TBL] [Abstract][Full Text] [Related]
28. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
29. Discovery of a Novel Specific Inhibitor Targeting Influenza A Virus Nucleoprotein with Pleiotropic Inhibitory Effects on Various Steps of the Viral Life Cycle.
Yang F; Pang B; Lai KK; Cheung NN; Dai J; Zhang W; Zhang J; Chan KH; Chen H; Sze KH; Zhang H; Hao Q; Yang D; Yuen KY; Kao RY
J Virol; 2021 Apr; 95(9):. PubMed ID: 33627391
[TBL] [Abstract][Full Text] [Related]
30. TMPRSS2 Is the Major Activating Protease of Influenza A Virus in Primary Human Airway Cells and Influenza B Virus in Human Type II Pneumocytes.
Limburg H; Harbig A; Bestle D; Stein DA; Moulton HM; Jaeger J; Janga H; Hardes K; Koepke J; Schulte L; Koczulla AR; Schmeck B; Klenk HD; Böttcher-Friebertshäuser E
J Virol; 2019 Nov; 93(21):. PubMed ID: 31391268
[TBL] [Abstract][Full Text] [Related]
31. Heterogeneity in transmissibility and shedding SARS-CoV-2 via droplets and aerosols.
Chen PZ; Bobrovitz N; Premji Z; Koopmans M; Fisman DN; Gu FX
Elife; 2021 Apr; 10():. PubMed ID: 33861198
[TBL] [Abstract][Full Text] [Related]
32. Novel Small Molecule Targeting the Hemagglutinin Stalk of Influenza Viruses.
Kim JI; Lee S; Lee GY; Park S; Bae JY; Heo J; Kim HY; Woo SH; Lee HU; Ahn CA; Bang HJ; Ju HS; Ok K; Byun Y; Cho DJ; Shin JS; Kim DY; Park MS; Park MS
J Virol; 2019 Sep; 93(17):. PubMed ID: 31167918
[TBL] [Abstract][Full Text] [Related]
33. Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19.
Dinda B; Dinda M; Dinda S; Chakraborty M
Eur J Med Chem Rep; 2022 Dec; 6():100079. PubMed ID: 36060987
[TBL] [Abstract][Full Text] [Related]
34. Emerging drug targets for antiretroviral therapy.
Reeves JD; Piefer AJ
Drugs; 2005; 65(13):1747-66. PubMed ID: 16114975
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in targeting viral proteases for the discovery of novel antivirals.
Steuber H; Hilgenfeld R
Curr Top Med Chem; 2010; 10(3):323-45. PubMed ID: 20166951
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-
Dinda B; Dinda S; Dinda M
Phytomed Plus; 2023 Feb; 3(1):100402. PubMed ID: 36597465
[TBL] [Abstract][Full Text] [Related]
37. Small-Molecule Inhibitor of Flaviviral NS3-NS5 Interaction with Broad-Spectrum Activity and Efficacy
Celegato M; Sturlese M; Vasconcelos Costa V; Trevisan M; Lallo Dias AS; Souza Passos IB; Queiroz-Junior CM; Messa L; Favaro A; Moro S; Teixeira MM; Loregian A; Mercorelli B
mBio; 2023 Feb; 14(1):e0309722. PubMed ID: 36622141
[TBL] [Abstract][Full Text] [Related]
38. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
Li J; Zhang C; Wu Z; Wang G; Zhao H
Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
[TBL] [Abstract][Full Text] [Related]
39. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
40. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
